Themes · Glp1

Narrative basket·№3 of the day·As of 2026-07-20

GLP-1 / Obesity/ №3

Incretin-class drugs, the next wave of obesity / metabolic therapeutics, and obesity-economy beneficiaries.

As of 2026-07-20, GLP-1 / Obesity ranks №3 among themes for that session with a composite score of 55/100 and median member RS of 68.

Composite: 55_/100
Median RS: 68
Breadth > 50dma: 77%
% at Highs: 0%
Accumulation: 46%
$-Vol Δ: -26%

Score history · last 60 sessionsLast 55·Range 35–79

Members_{13 tickers}

Ticker / whyRSTrendHighAccum$Vol

MBXMBX; once-monthly GLP-1/GIP

RS 98

50D

ACCUM

-32%$38.9M$57.1M

ARWRArrowhead; RNAi cardiometabolic

RS 95

-28%$172.7M$241.1M

LLYMounjaro/Zepbound franchise

RS 83

50D

ACCUM

-17%$3.0B$3.7B

GPCRStructure; oral GLP-1 Phase 3

RS 82

50D

ACCUM

-55%$19.1M$42.5M

MRKlicensed oral GLP-1; MASH

RS 79

50D

-32%$961.4M$1.4B

SRRKScholar Rock; lean-mass preservation

RS 71

50D

ACCUM

-53%$45.5M$97.6M

AMGNMariTide pipeline

RS 65

50D

-24%$699.9M$924.0M

VKTXnext-gen dual-agonist

RS 59

50D

-38%$69.5M$112.0M

REGNmuscle-preserving obesity combos

RS 51

50D

ACCUM

-30%$420.0M$596.5M

NVOOzempic/Wegovy franchise

RS 47

50D

-33%$361.9M$543.3M

HIMSobesity telehealth; Novo distribution deal

RS 36

50D

-49%$272.6M$533.9M

ALTAltimmune; GLP-1/glucagon, MASH Phase 3

RS 21

ACCUM

-49%$7.3M$14.4M

KLRAKailera; late-stage obesity (Apr 2026 IPO)

RS --

-72%$6.8M$24.2M

Loading…

Members13 tickers

Members13 tickers

Members_{13 tickers}

Members_{13 tickers}